Compare Citius Pharmaceuticals Inc (CTXR) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kaltura Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Kaltura Inc is far larger — about 14.6× Citius Pharmaceuticals Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Kaltura Inc for 21 Days on average.
| CTXR | KLTR | |
|---|---|---|
Market Cap | $13.62M | $199.08M |
Volume | 132,438 | 175,927 |
Sector | Health | Technology |
52-Week High | $1.82 | $1.89 |
52-Week Low | $0.48 | $1.08 |
Typical Hold Time | 16 Days | 21 Days |
Enterprise Value | $3.79M | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
KLTR trades at $1.33, up 3.91% today, showing positive momentum despite a bearish technical signal. The company demonstrates improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent earnings beats and industry recognition for AI-powered video platforms provide optimism, though negative ROE (-134.25%) and high debt levels remain concerns.
KLTR presents a turnaround story with improving financials and strong AI positioning, but faces significant execution risks. The stock offers speculative upside if the company can achieve profitability, though current valuation metrics (P/S 1.08, EV/EBITDA 271.59) reflect market skepticism about near-term earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
